PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
C. foetida extract (100mg daily) decreased modified Kupperman Menopausal Index scores in early postmenopausal women [PMID:29198157].
Postmenopausal women receiving C. foetida extract had the lowest prevalence of breast tenderness compared to those on hormone therapy [PMID:29542344].
Combination therapy of C. foetida and adefovir significantly reduced median intrahepatic HBV covalently closed circular DNA (cccDNA) levels compared to adefovir monotherapy [PMID:27073640].
Prevents osteoporosis by inhibiting autophagy of osteoclasts via CB2R and ERα (studied in vitro and in OVX rat models) [PMID:40680333].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 38914214 (2024) — Antidepressant-like effects of Cimicifuga dahurica (Turcz.) Maxim. via modulation of monoamine regulatory pathways. · Physiology & behavior
- 2.PMID: 40680333 (2025) — Cimicifuga foetida and C. racemosa prevent postmenopausal osteoporosis by inhibiting autophagy of osteoclasts via CB2R and ERα. · Phytomedicine : international journal of phytotherapy and phytopharmacology
- 3.PMID: 32464254 (2020) — Cycloartane triterpene glycosides from rhizomes of Cimicifuga foetida L. with lipid-lowering activity on 3T3-L1 adipocytes. · Fitoterapia
- 4.PMID: 15621617 (2005) — Chemical constituents from Cimicifuga foetida. · Journal of Asian natural products research
- 5.PMID: 25136911 (2014)